Co-Diagnostics Inc is a biotechnology company that focuses on the development and manufacturing of molecular diagnostic tests used to detect diseases
The company specializes in the design of innovative testing solutions that leverage its proprietary technologies for amplification and detection of nucleic acids. Co-Diagnostics aims to provide accurate and timely diagnostic tools that facilitate the identification of various pathogens, aiding in disease prevention and management. Through its commitment to enhancing diagnostic capabilities, the company supports healthcare providers and public health initiatives.
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.
Co-Diagnostics (NASDAQCODX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that Co-Diagnostics will report an earnings per share (EPS) of $-0.04.
Benzinga Pro data, Co-Diagnostics (NASDAQCODX) reported Q2 sales of $5.02 million. Earnings fell to a loss of $2.69 million, resulting in a 122.93% decrease from last quarter.
